Literature DB >> 20609419

A novel toxicity scoring system treating toxicity response as a quasi-continuous variable in Phase I clinical trials.

Zhengjia Chen1, Mark D Krailo, Stanley P Azen, Mourad Tighiouart.   

Abstract

In almost all current Phase I designs, toxicity response is treated coarsely as a binary indicator of dose limiting toxicity (DLT) and a lot of useful toxicity information is discarded. We are the first to establish a novel toxicity scoring system to treat toxicity response as a quasi-continuous variable and utilize all toxicities in Phase I trial. The generally accepted and objective parts, such as a logistic function, grade and type of toxicity, and whether the toxicity is DLT, are used so that the toxicity scoring system is relatively objective. Our toxicity scoring system has been successfully applied to an isotonic design (ID) to develop an extended isotonic design (EID). Simulation study and application of EID to the data of a real Phase I trial demonstrate that EID can always estimate a more accurate maximum tolerated dose (MTD) according to the exact toxicity profile under any toxicity profiles without additional cost or length of the trial. These cannot be accomplished in designs using a binary indicator of DLT, such as Standard 3+3 design, ID, and continual reassessment method (CRM). Moreover, our EID is relatively objective, model free, and simple to use. Our toxicity scoring system can also be applied to other designs, such as CRM and escalation with overdose control (EWOC), to improve their efficiency and accuracy in MTD estimation by utilizing all toxicities. Our novel toxicity scoring system and EID may help to begin a new era in which toxicity response is treated as a continuous variable. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20609419      PMCID: PMC4871599          DOI: 10.1016/j.cct.2010.05.010

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  12 in total

1.  Statistical properties of the traditional algorithm-based designs for phase I cancer clinical trials.

Authors:  Y Lin; W J Shih
Journal:  Biostatistics       Date:  2001-06       Impact factor: 5.899

Review 2.  Competing designs for phase I clinical trials: a review.

Authors:  William F Rosenberger; Linda M Haines
Journal:  Stat Med       Date:  2002-09-30       Impact factor: 2.373

Review 3.  Phase I studies of chemotherapeutic agents in cancer patients: a review of the designs.

Authors:  Douglas M Potter
Journal:  J Biopharm Stat       Date:  2006       Impact factor: 1.051

4.  Range and trend of expected toxicity level (ETL) in standard A + B designs: a report from the Children's Oncology Group.

Authors:  Zhengjia Chen; Mark D Krailo; Junfeng Sun; Stanley P Azen
Journal:  Contemp Clin Trials       Date:  2008-10-29       Impact factor: 2.226

5.  Continual reassessment method: a likelihood approach.

Authors:  J O'Quigley; L Z Shen
Journal:  Biometrics       Date:  1996-06       Impact factor: 2.571

6.  Continual reassessment method: a practical design for phase 1 clinical trials in cancer.

Authors:  J O'Quigley; M Pepe; L Fisher
Journal:  Biometrics       Date:  1990-03       Impact factor: 2.571

7.  Design and analysis of phase I clinical trials.

Authors:  B E Storer
Journal:  Biometrics       Date:  1989-09       Impact factor: 2.571

8.  Some practical improvements in the continual reassessment method for phase I studies.

Authors:  S N Goodman; M L Zahurak; S Piantadosi
Journal:  Stat Med       Date:  1995-06-15       Impact factor: 2.373

9.  Cancer phase I clinical trials: efficient dose escalation with overdose control.

Authors:  J Babb; A Rogatko; S Zacks
Journal:  Stat Med       Date:  1998-05-30       Impact factor: 2.373

10.  The continual reassessment method for multiple toxicity grades: a Bayesian quasi-likelihood approach.

Authors:  Z Yuan; R Chappell; H Bailey
Journal:  Biometrics       Date:  2007-03       Impact factor: 2.571

View more
  15 in total

1.  Phase 1 adaptive dose-finding study of neoadjuvant gemcitabine combined with radiation therapy for patients with high-risk extremity and trunk soft tissue sarcoma.

Authors:  William W Tseng; Shouhao Zhou; Christina A To; Peter F Thall; Alexander J Lazar; Raphael E Pollock; Patrick P Lin; Janice N Cormier; Valerae O Lewis; Barry W Feig; Kelly K Hunt; Matthew T Ballo; Shreyaskumar Patel; Peter W T Pisters
Journal:  Cancer       Date:  2015-07-15       Impact factor: 6.860

2.  Advances in Statistical Approaches Oncology Drug Development.

Authors:  Anastasia Ivanova; Gary L Rosner; Olga Marchenko; Tom Parke; Inna Perevozskaya; Yanping Wang
Journal:  Ther Innov Regul Sci       Date:  2014-01       Impact factor: 1.778

3.  Dose escalation with over-dose and under-dose controls in Phase I/II clinical trials.

Authors:  Zhengjia Chen; Ying Yuan; Zheng Li; Michael Kutner; Taofeek Owonikoko; Walter J Curran; Fadlo Khuri; Jeanne Kowalski
Journal:  Contemp Clin Trials       Date:  2015-05-24       Impact factor: 2.226

Review 4.  An overview of the BOIN design and its current extensions for novel early-phase oncology trials.

Authors:  Revathi Ananthakrishnan; Ruitao Lin; Chunsheng He; Yanping Chen; Daniel Li; Michael LaValley
Journal:  Contemp Clin Trials Commun       Date:  2022-06-13

5.  Modeling adverse event counts in phase I clinical trials of a cytotoxic agent.

Authors:  Daniel G Muenz; Thomas M Braun; Jeremy Mg Taylor
Journal:  Clin Trials       Date:  2018-05-19       Impact factor: 2.486

6.  Dose escalation with overdose control using a quasi-continuous toxicity score in cancer Phase I clinical trials.

Authors:  Zhengjia Chen; Mourad Tighiouart; Jeanne Kowalski
Journal:  Contemp Clin Trials       Date:  2012-04-25       Impact factor: 2.226

7.  Escalation with overdose control using all toxicities and time to event toxicity data in cancer Phase I clinical trials.

Authors:  Zhengjia Chen; Ye Cui; Taofeek K Owonikoko; Zhibo Wang; Zheng Li; Ruiyan Luo; Michael Kutner; Fadlo R Khuri; Jeanne Kowalski
Journal:  Contemp Clin Trials       Date:  2014-02-12       Impact factor: 2.226

8.  Repeated measures dose-finding design with time-trend detection in the presence of correlated toxicity data.

Authors:  Jun Yin; Xavier Paoletti; Daniel J Sargent; Sumithra J Mandrekar
Journal:  Clin Trials       Date:  2017-08-02       Impact factor: 2.486

9.  Designing Dose-Finding Phase I Clinical Trials: Top 10 Questions That Should Be Discussed With Your Statistician.

Authors:  Shing M Lee; Nolan A Wages; Karyn A Goodman; A Craig Lockhart
Journal:  JCO Precis Oncol       Date:  2021-02-01

10.  Interactive Software "Isotonic Design using Normalized Equivalent Toxicity Score (ID-NETS©TM)" for Cancer Phase I Clinical Trials.

Authors:  Zhengjia Chen; Zhibo Wang; Haibin Wang; Taofeek K Owonikoko; Jeanne Kowalski; Fadlo R Khuri
Journal:  Open Med Inform J       Date:  2013-04-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.